Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Restricts Cymbalta in Major Depression

Duloxetine (Cymbalta) has been restricted for use in Scotland by the Scottish Medicines Consortium.

This decision is based upon limited evidence of efficacy in comparison to other antidepressants in major depression. The product is therefore restricted to use in patients who are unable to tolerate or have not responded to initial treatment options.

The recommendation made here still stands that treatment with this drug in Primary Care is not recommended based on the fact that most patients in primary care have mild depression.

Action: Duloxetine should not be used as an antidepressant in a Primary Care Setting.

Share 'SMC Restricts Cymbalta in Major Depression' on Email Share 'SMC Restricts Cymbalta in Major Depression' on Delicious Share 'SMC Restricts Cymbalta in Major Depression' on Digg Share 'SMC Restricts Cymbalta in Major Depression' on Facebook Share 'SMC Restricts Cymbalta in Major Depression' on Google+ Share 'SMC Restricts Cymbalta in Major Depression' on reddit Share 'SMC Restricts Cymbalta in Major Depression' on StumbleUpon Share 'SMC Restricts Cymbalta in Major Depression' on Twitter

atomic-wealth

No Comments to “SMC Restricts Cymbalta in Major Depression”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,658 spam comments.

atomic-wealth
fond-illness
summer